Malaria vaccines may be missing some of the parasite’s most vulnerable targets, according to a new study from researchers at the Ragon Institute of Mass General Brigham, MIT and Harvard. The work, published in the Journal of Experimental Medicine, identifies an immune-response gap in the two vaccines currently recommended by the World Health Organization and tests a strategy designed to close it. The findings suggest that future malaria vaccines could become more effective not by relying on a single dominant target, but by directing the immune system toward several regions of the parasite at once.
Malaria is caused by Plasmodium parasites transmitted through the bites of infected mosquitoes. The disease kills more than half a million people each year, with young children in sub-Saharan Africa bearing most of the burden. The WHO now recommends two vaccines, RTS,S and R21, both of which are based on the parasite’s circumsporozoite protein, or PfCSP. This protein coats the parasite’s sporozoite stage, which travels from the mosquito into the bloodstream and then to the liver. Antibodies that bind PfCSP can block sporozoites before they infect liver cells, making the protein an important focus for vaccine development.
PfCSP, however, is not an immunologically uniform surface. It contains several regions, including a long sequence of repeated amino acids known as the major repeat, as well as a shorter minor repeat and a junctional region connecting distinct parts of the protein. RTS,S and R21 prominently display the major repeat. This region is highly immunogenic, meaning that it readily stimulates the production of antibodies. Yet the most potent anti-malarial antibodies identified in previous research often recognize the minor repeat or the junction, regions that are more difficult for the immune system to target and that are not directly presented by either current vaccine.
The Batista Lab sought to determine whether vaccination against the major repeat might nevertheless generate some antibodies against these additional regions. First authors Ja-Hyun Koo and Prabhanshu Tripathi and their colleagues created mouse models carrying human antibody genes. These genetically engineered animals contained immune-cell precursors programmed to produce antibodies corresponding to known human responses against different parts of PfCSP. Each mouse line therefore represented a distinct potential antibody response, allowing the researchers to track which B cells were activated by particular vaccine designs.
When the mice received the same PfCSP fragment used in R21, the result was highly selective. B cells directed against the major repeat expanded, while cells capable of producing antibodies against the minor repeat and junction remained largely inactive. The researchers then tested the complete PfCSP protein, reasoning that the presence of every region might broaden the response. Instead, the major repeat continued to dominate. Its strong immunogenicity effectively outcompeted the less accessible targets, a phenomenon known as immunodominance. In practical terms, the immune system focused its resources on the region it recognized most easily rather than distributing them across the entire protein.
The researchers next tested whether a deliberately simplified antigen could expose the immune system to a neglected target. They used a short peptide containing the minor repeat but lacking the major repeat and other competing regions. This focused design changed the response. B cells capable of recognizing the minor repeat became activated, multiplied and persisted for weeks. They also accumulated somatic mutations, the genetic changes that occur during affinity maturation as B cells refine their antibodies in specialized immune structures. These changes resembled those observed in mature human antibodies known to protect against malaria, indicating that the peptide had not merely triggered a response but had helped guide it toward a more developed state.
The strongest results came from combining different antigen formats. The researchers paired the R21-style PfCSP protein with two short peptides, one representing the minor repeat and the other representing the junction. This formulation activated B-cell populations against all three regions simultaneously. The resulting antibodies recognized the major repeat, minor repeat and junction, creating a broader response than the current vaccine design produces on its own. When the immunized mice were later exposed to malaria parasites, this combination was the only strategy tested that significantly reduced the number of parasites reaching the liver, the critical early stage at which infection becomes established.
The study also examined why some antibodies protect better than others. In collaboration with scientists at the National Institutes of Health, Johns Hopkins University and Columbia University, the team engineered antibody variants that bound PfCSP as much as 10 times more tightly. Surprisingly, stronger binding did not automatically result in greater protection. The observation suggests that antibody affinity—the physical strength of the interaction between an antibody and its target—is only one part of the equation. The angle of binding, the precise site recognized and the ability of an antibody to interfere with the parasite’s movement or cell invasion may be equally important. An antibody that grips tightly but approaches the protein in an ineffective orientation may provide less protection than one with a weaker interaction but a more strategically positioned binding site.
The findings do not imply that RTS,S or R21 should be abandoned. Instead, they point toward a possible way to supplement existing vaccines with additional antigens that redirect immune attention toward PfCSP regions currently overlooked. A multi-component formulation could, in principle, combine the accessibility of the major repeat with the protective potential of the minor repeat and junction. Such an approach would need to be evaluated in further animal studies and, ultimately, in human clinical trials to determine its safety, durability and ability to prevent infection in regions where malaria transmission is intense. Even so, the work provides a practical framework for overcoming immunodominance and designing malaria vaccines that generate broader, more functionally effective antibody responses.
Subject of Research: Animals
Article Title: Overcoming Immunogenic Gaps in Malaria Subunit Vaccines by Broadening CSP-Regions Targeted
Web References: Ragon Institute Batista Lab — https://ragoninstitute.org/lab/batista/
References: Journal of Experimental Medicine, DOI: 10.1084/jem.20260846
Keywords: Malaria, malaria vaccines, RTS,S, R21, PfCSP, circumsporozoite protein, antibodies, B cells, immunodominance, peptide vaccines, vaccine design, Plasmodium parasites
Tags: circumsporozoite protein (PfCSP)immune response targeting multiple parasite regionsimmune system targeting in malariamalaria parasite vulnerabilitiesmalaria prevention in sub-Saharan Africamalaria vaccine developmentmalaria vaccine efficacy gapsmalaria vaccine enhancement strategiesmalaria vaccine research and innovationpeptide-based vaccine improvementsPlasmodium parasite immune responseRTSS and R21 malaria vaccines
